Xenetic Biosciences shares jump 10.77% intraday after reporting 2025 financial results and advancing DNase technology toward Phase 1 trials.

Xenetic Biosciences surged 10.77% intraday following the release of its 2025 full-year financial results and operational updates. The company highlighted progress in DNase-based immuno-oncology programs, including preclinical data supporting therapeutic potential for pancreatic cancer and lymphoma, as well as advancements toward U.S. IND submission. Despite a $2.7 million net loss, the report emphasized disciplined capital use and a 19% increase in royalty revenue from Takeda. Notably, cash reserves rose to $7.9 million, driven by a $4.0 million public offering in October 2025. The announcement of strategic alternatives to maximize shareholder value and positive translational research outcomes, including collaborations with Scripps Research, reinforced investor confidence in the company’s pipeline and long-term growth prospects.